Recombinant Human Bcl-2-like protein 1(BCL2L1),partial

Code CSB-EP002613HU
Size US$1726
  • (Tris-Glycine gel) Discontinuous SDS-PAGE (reduced) with 5% enrichment gel and 15% separation gel.

Have Questions? Leave a Message or Start an on-line Chat

Product Details

Purity Greater than 90% as determined by SDS-PAGE.
Target Names BCL2L1
Uniprot No. Q07817
Research Area Cancer
Alternative Names Apoptosis regulator Bcl X; Apoptosis regulator Bcl-X; Apoptosis regulator BclX; B cell lymphoma 2 like; B2CL1_HUMAN; Bcl 2 like 1 protein; Bcl X; Bcl xL; BCL XL/S; Bcl xS; Bcl-2-like protein 1; Bcl2 Like 1; Bcl2 related gene; Bcl2-L-1; BCL2L; Bcl2l1; BCLX; BclXL; BclXs; DKFZp781P2092; PPP1R52; Protein phosphatase 1 regulatory subunit 52
Species Homo sapiens (Human)
Source E.coli
Expression Region 1-209aa
Note: The complete sequence including tag sequence, target protein sequence and linker sequence could be provided upon request.
Mol. Weight 39.4kDa
Protein Length Partial
Tag Info N-terminal 6xHis-SUMO-tagged
Form Liquid or Lyophilized powder
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.
Buffer If the delivery form is liquid, the default storage buffer is Tris/PBS-based buffer, 5%-50% glycerol.
Note: If you have any special requirement for the glycerol content, please remark when you place the order.
If the delivery form is lyophilized powder, the buffer before lyophilization is Tris/PBS-based buffer, 6% Trehalose, pH 8.0.
Reconstitution We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Please reconstitute protein in deionized sterile water to a concentration of 0.1-1.0 mg/mL.We recommend to add 5-50% of glycerol (final concentration) and aliquot for long-term storage at -20°C/-80°C. Our default final concentration of glycerol is 50%. Customers could use it as reference.
and FAQs
Protein FAQs
Storage Condition Store at -20°C upon receipt, aliquoting is necessary for mutiple use. Avoid repeated freeze-thaw cycles.
Shelf Life The shelf life is related to many factors, storage state, buffer ingredients, storage temperature and the stability of the protein itself.
Generally, the shelf life of liquid form is 6 months at -20°C/-80°C. The shelf life of lyophilized form is 12 months at -20°C/-80°C.
Lead Time Delivery time may differ from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Notes Repeated freezing and thawing is not recommended. Store working aliquots at 4°C for up to one week.
Datasheet & COA Please contact us to get it.

Target Data

Function Potent inhibitor of cell death. Inhibits activation of caspases. Appears to regulate cell death by blocking the voltage-dependent anion channel (VDAC) by binding to it and preventing the release of the caspase activator, CYC1, from the mitochondrial membrane. Also acts as a regulator of G2 checkpoint and progression to cytokinesis during mitosis.; FUNCTION
Gene References into Functions
  1. Study shows that multiple ion transporters mediate the rise in pH that increases the rate of Bcl-xL deamidation in response to DNA damage in certain cells. Additionally, deamidation of Bcl-xL is intramolecularly catalyzed in a manner that is dependent upon two conserved histidines near each of the deamidation sites and that they may function together as a pH-sensitive switch. PMID: 29694915
  2. hTERT contains a BH3-like motif, a short peptide sequence found in BCL-2 family proteins, and interacts with anti-apoptotic BCL-2 family proteins MCL-1 and BCL-xL PMID: 29937479
  3. Study demonstrated that lncRNA-HEIH regulates miR-939 expression through transcriptional repression of Bcl-xL promoting colorectal tumorigenesis. PMID: 29081216
  4. Results showed that the expressions of RIP2 and BclxL were positively correlated with the malignant grade of astrocytoma. RIP2 promoted human glioblastoma cell proliferation by inducing expression of BclxL. PMID: 29693188
  5. BCL-XL has a role in modulating RAS signalling to favor breast cancer cell stemness PMID: 29066722
  6. Bcl-xL degradation during endoplasmic reticulum stress-induced apoptosis is mediated by RNF183.RNF183 ubiquitinates Bcl-xL. PMID: 29507230
  7. BCL-XL promotes stemness and contributes to the aggressiveness of both melanoma and glioblastoma. PMID: 29238043
  8. inhibition of the BCL2 family member BCLxL resulted in nanomolar potency against human synovial sarcoma cell lines and 50% tumor reduction in a genetically engineered mouse model PMID: 28851813
  9. inhibition of Bcl-xL induces significantly more apoptosis in IDH1-mutated cells than in wild-type IDH1 cells. PMID: 29057925
  10. CCAT1 is upregulated in docetaxel-resistant lung adenocarcinoma cells; its oncogenic function depends on sponging of let-7c, which releases Bcl-xl, promoting the acquisition of chemoresistance and epithelial-to-mesenchymal transition phenotypes PMID: 27566568
  11. In the epithelial ovarian cancer stem cells, 40% knock-down of Bclxl expression was sufficient to induce the full activation of caspases. Bclxl expression levels in EOC cells is dynamic and can be regulated by microenvironments that are enriched with the pro-inflammatory cytokine IL-6 such as the cancer stem cell and adipocyte niches. PMID: 28012060
  12. Study reports the interaction of BCL-XL with RASSF6. BCL-XL inhibits the interaction between RASSF6 and MDM2 and suppresses p53 expression. Consequently, BCL-XL antagonizes RASSF6-mediated apoptosis. Thus, the inhibition of RASSF6-mediated apoptosis also underlies the prosurvival role of BCL-XL. PMID: 29193479
  13. These results show that mRNA expression in centenarians is unique and reveals that Bcl-xL plays an important role in exceptional aging. PMID: 27794564
  14. that Ubiquitin-specific peptidase 18 directly bind to BCL2L1 and positively regulated its expression in hepatocellular carcinoma cells PMID: 28709980
  15. High BCL-XL expression is associated with breast cancer. PMID: 28223545
  16. The the expression of the full-length, wildtype form of PRMT2 promotes an increase in the BCL-X(L)/BCL-X(s) ratio in TNF-alpha or LPS stimulated cells. PMID: 28057797
  17. Bcl-xL is a driver in colorectal tumorigenesis and cancer progression. PMID: 27537525
  18. These data show that Mcl-1 is dispensable for the regulation of apoptosis during infection with different large DNA viruses.Bcl-XL, on the other hand, can be important to maintain survival of virus-infected cells PMID: 27537523
  19. BC200 knockout suppresses tumor cell growth in vitro and in vivo by expression of the pro-apoptotic Bcl-xS isoform. PMID: 27277684
  20. Bcl-xL inhibits GAS-induced autophagy directly by suppressing autophagosome-lysosome fusion and indirectly by suppressing GAS internalization via interaction with Beclin 1-UVRAG. PMID: 28085926
  21. The combination of 2-deoxyglucose (2-DG) and ABT-199 initiated cell death through the reduction of myeloid cell leukemia sequence 1 protein (Mcl-1) expression and c-Jun N-terminal kinase 1 (JNK1) activation and subsequent Bcl-xL protein degradation. PMID: 28038464
  22. Bcl-xL is an exosomal caspase-3 substrate and that this processing is required for the uptake of exosomes by recipient cells. PMID: 27742710
  23. dynamic Bcl-xL(S49) and (S62) phosphorylation/dephosphorylation cycles are important in the maintenance of chromosome integrity during mitosis in normal cells PMID: 27398719
  24. Mono treatment with lexatumumab was not sufficient to induce apoptosis in pancreatic cancer cells, whereas focal adhesion kinase inhibitor PF573228 significantly sensitized lexatumumab-induced apoptosis. Western blotting analysis revealed that lexatumumab and PF573228 combination treatment increased death receptor 5 but decreased Bcl-xL expression. PMID: 28459212
  25. Reduced lifetimes of the donor were partially restored by coexpression of HIF-1alpha or Bcl-xL, binding proteins of IPAS in the nucleus and mitochondria, respectively. PMID: 28003430
  26. mechanistic studies, inhibition of SRC and PKCdelta completely ablated the ability of MDA-7/IL-24 to reduce the Bcl-x(L)/(s) mRNA ratio and cell viability. These findings show that Bcl-x(s) expression is an important mediator of MDA-7/IL-24-induced cytotoxicity requiring the SRC/PKCdelta signaling axis in NSCLC cells. PMID: 27519412
  27. Resistance induced in newly formed cancer stem cells is mediated by the anti-apoptotic molecule BCL-XL and inhibition of BCL-XL with the BH3 mimetic ABT-737 sensitizes these cancer cells toward chemotherapy. PMID: 25483065
  28. we discovered that deletions involving the PARK2 gene are significantly anti-correlated with focal amplifications of the gene encoding BCL-XL. PMID: 28038320
  29. The C-terminal tail of BCL-XL forms a membrane-embedded alpha-helix that anchors the protein's globular head to the lipid bilayer membrane, yet retains a significant degree of conformational dynamics. PMID: 26923059
  30. Bcl-xL overexpression may be closely related to the dynamic of the pathogenesis and development of tongue carcinoma. PMID: 25550772
  31. Results provide evidence that microRNA 421 induces apoptosis of cervical cancer cells via down-regulation of Bcl-xL. PMID: 27886335
  32. We conclude that Bcl-x plays a role in regulation of HSC apoptosis and modulation of Bcl-x alternative splicing may become a novel molecular therapy for liver fibrosis. PMID: 27579319
  33. Intracellular expression of Bcl-xL was significantly greater in CD4+ T-cells, CD8+ T-cells, and NK cells of infants with bronchiolitis compared to controls. PMID: 26541527
  34. Data indicate the potential of functionalized Apt-carbon nanotubes conjugates for increasing the induction of apoptosis in Mucin-1 (MUC1) positive tumor cells by suppression of Bcl-xL transcript. PMID: 26731195
  35. Genetic and pharmacological inhibition of BCL-W and BCL-XL causes directed elimination of senescent cells. PMID: 27048913
  36. miR-133a and miR-326 downregulate the mRNA expression of Bcl-xl in HepG2 cells. PMID: 26239225
  37. Bcl-xL is a key factor in polyploidization resistance in acute myeloid leukemia PMID: 26188358
  38. This study lends new molecular insights into understanding the binding specificity of BH3 ligands to BclXL with important consequences on the design of novel anticancer drugs. PMID: 24114183
  39. TCERG1 sensitizes a cell to apoptotic agents, thus promoting apoptosis by regulating the alternative splicing of both the Bcl-x and Fas/CD95 genes. PMID: 26462236
  40. Data show that JAK/STAT signaling inhibition is potentiated by Bcl-xL (B-cell lymphoma-extra large) blockade in interleukin 2 (IL-2) dependent adult T-cell leukemia cells. PMID: 26396258
  41. Data suggest BCL2-like 1 protein (BCL2L1) and deleted in liver cancer 1 protein (DLC1) as potential druggable targets for specific subsets of gastric cancer (GC) cases. PMID: 26401016
  42. CD40 signaling led to sustained ERK1/2 activation and up-regulation of Bcl-xL in BCR-primed HF1A3 germinal center B cells.[BCR] PMID: 26054744
  43. miR-326 targets antiapoptotic Bcl-xL and mediates apoptosis in human platelets. PMID: 25875481
  44. alpha4 is an important regulatory molecule of apoptosis and Bcl-xL phosphorylation induced by BCR crosslinking. PMID: 25876659
  45. These findings suggested that Bcl-xL may be a promising therapeutic approach for the treatment of NSCLC PMID: 25683634
  46. Weakening the inhibition of either Bax or ceramide channels decreased the ability of Bcl-xL to protect cells from apoptosis in a stimulus-dependent manner. PMID: 26215742
  47. BCL-XL up-regulation by STAT3 contributes to mutant KRAS-mediated apoptosis resistance. Such resistance can be overcome by potent BIM induction and concurrent BCL-XL antagonism PMID: 26245900
  48. BCL2L1 mutation mediates copy number variant 20q11.21 in hESC lines. PMID: 24286026
  49. We conclude that enhanced Bcl-xL levels confer resistance to cells upon epithelial to mesenchymal transformation PMID: 25473892
  50. the combination of simultaneous siRNA-mediated knockdown of antiapoptotic Bcl-xL and survivin-a multitarget molecular-based therapy-and conventional chemotherapy shows great potential for improving bladder cancer treatment. PMID: 23749114
  51. PKM2 is an active protein kinase, and promotes liver cancer cell proliferation by up-regulating HIF-1alpha and Bcl-xL expression. PMID: 25661370
  52. In addition to the interaction with various pro-apoptotic proteins, the association with certain mitochondrial proteins such as DNA-PKcs and prohibitins might augment the survival function of BCL-xL in adenovirus infected cells. PMID: 25965792
  53. A genetic approach, through siRNA-mediated down-regulation of AKT, MCL-1, and BCL-xL, significantly decreased cell survival, demonstrating the importance of these cell survival factors for ABT-199 resistance. PMID: 25590803
  54. Bcl-X(L) and p53-mediated amplification mechanisms played important roles in the sensitization of non-small-cell lung carcinoma cells to TRAIL-mediated apoptosis PMID: 25522273
  55. These findings indicate that eosinophil survival is largely regulated by betac chain-induced NF-kappaB activation and subsequent induction of Bcl-x PMID: 25862560
  56. Conformation of BCL-XL upon membrane integration:membrane-bound BCL-XL maintains globular fold and has enhanced binding affinity. PMID: 25731750
  57. Mitotic cells harboring aneuploidy with micro-, bi-, or multi-nucleated cells, and cells that fail to resolve undergo mitosis within 6 h were also made with cells expressing the phosphorylation mutant Bcl-xL(Ser49Ala) and dual mutant Bcl-xL(Ser49/62Ala). PMID: 24621501
  58. MiR-491-5p-induced apoptosis in ovarian carcinoma by inhibition of both BCL-XL and EGFR leading to BIM activation. PMID: 25299770
  59. the Bcl-xL R139A mutation disrupts binding to all helices but the Bad-BH3 peptide PMID: 25844633
  60. T. vaginalis induces mitochondria-dependent apoptosis in SiHa cells through the dissociation of Bcl-xL/Bim and Mcl-1/Bim complexes. PMID: 25343522
  61. let-7b increased 5-FU sensitivity by repressing Bcl-xl expression in HCC cells. PMID: 25333670
  62. IL-17 has a direct effect on the decrease of Bcl-xl PMID: 25975002
  63. miR-608 and miR-34a regulate chordoma malignancy by regulating EGFR, MET and Bcl-xL PMID: 24621885
  64. The BCL2L1-PGAM5-FUNDC1 axis is critical for receptor-mediated mitophagy. PMID: 25126723
  65. Bcl-xl protein expression is downregulated by low-dose radiation alone or in combination with high-dose radiation (LDR/HDR). PMID: 25060925
  66. The crystal structures of BCL-W and BCL-XL, along with cellular, studies reveal critical features of the BH3 domains of pro-survival proteins that distinguish them functionally from their pro-apoptotic counterparts. PMID: 25371206
  67. Bcl-xL does not have a role in the diagnosis of colon adenocarcinomas or the detection of the degree of differentiation PMID: 25110240
  68. normal activity of EVI1 or that HIC1 is masking the EVI1 interface required to bind the Bcl-xL promoter and thus blocking the action of EVI1 on Bcl-xL PMID: 24907396
  69. Bcl-xL silencing induces alterations in hsa-miR-608 expression and subsequent cell death in A549 and SK-LU1 human lung adenocarcinoma cells PMID: 24339958
  70. Suggest role for interaction between Na-K-ATPase and Bcl-2 proteins BclXL and Bak in controlling cell survival/apoptosis. PMID: 25318106
  71. Apoptotic priming under conditions of mitotic arrest relies, at least in part, on the phosphorylation on serine 62 of Bcl-xL, which modulates its interaction with Bax and its sensitivity to ABT-737. PMID: 24922075
  72. A signaling pathway consisting of PI3K/Akt-NF-kappaB-Bcl-xL regulates macrophage survival during differentiation. In contrast, in differentiated macrophages, Bcl-xL expression is independent of PI3K/Akt activation. PMID: 25225677
  73. FBI-1 affects recruitment of SAM68 on the BCL-X transcript through an HDAC dependent mechanism. PMID: 24514149
  74. BCL2L1 showed the greatest difference between Li responders and non-responders in patients with bipolar disorder PMID: 23670706
  75. Syk binds robustly to nucleolin and phosphorylates it on tyrosine, enhancing its ability to bind and stabilize the Bcl-x(L) mRNA. PMID: 25092868
  76. inhibition of FAK, PYK2 and BCL-XL synergistically enhances apoptosis in ovarian clear cell carcinoma cell lines PMID: 24523919
  77. Study shows that Parkin-dependent mitophagy is antagonized by prosurvival members of the Bcl-2 family, Bcl-xL and Mcl-1 in a Beclin-1-independent manner. PMID: 24999239
  78. Plant polysaccharide SGP-2 exerts anti-tumor effect in osteosarcoma cells through intrinsic apoptotic pathway controlled by ERK/eIF4F/Bcl-XL pathway. PMID: 25025927
  79. IL-33/ST2 axis promotes mast cell survival via BCLXL. PMID: 24982172
  80. The BCL-xl/p53 complex is characterized by NMR spectroscopy. PMID: 24814347
  81. Gain of 20q11.21 in human embryonic stem cells improves cell survival by increased expression of Bcl-xL. PMID: 24217388
  82. PP6 activity is regulated to control apoptosis by modulating Ser(62) phosphorylation of Bcl-xL, which results in its polyubiquitination and degradation. PMID: 24808369
  83. Data indicate that Bcl-xL appears to be auto-inhibited by its C-terminal tail that embeds into and covers the hydrophobic binding pocket. PMID: 24116174
  84. PI3K/mTOR dual inhibitor NVP-BEZ235 decreases Mcl-1 expression and sensitizes ovarian carcinoma cells to Bcl-xL-targeting strategies, provided that Bim expression is induced. PMID: 24650799
  85. These findings suggest that Bcl-xl overexpression exerts an anti-apoptotic and protective effect on EC function PMID: 24217227
  86. BCl-xL gene expression is a good indicator for complete tumor response in patients with oral cancer, treated with radiotherapy. PMID: 22987535
  87. Data indicate that signal transducer and activator of transcription-6 (STAT6), a direct target of miR-361-5p, enhances the expression of B-cell lymphoma-extra large (Bcl-xL), while miR-361-5p inhibits its expression through STAT6. PMID: 24491557
  88. Data show that SET accumulation up-regulated hnRNPK mRNA and total/phosphorylated protein, promoted hnRNPK nuclear location, and reduced Bcl-x mRNA levels. PMID: 24508256
  89. Increased expression of Bcl-2, Bcl-xL and catalase proteins are important mechanisms contributing to transformed cell oncogenic properties. PMID: 23828460
  90. Only the increased phosphorylation of Bcl-XL. PMID: 22949227
  91. Downregulation of the Notch pathway through gamma-secretase inhibitors (GSIs)involves an increase in protein levels of the anti-apoptotic Bcl-2 family members Mcl-1 and/or Bcl-xL which resulted in reduced Bax and Bak activation. PMID: 23887890
  92. Instead, Bcl-xL -blocked apoptosis resulting from hypoxia and/or nutrient loss associated with the inhibition of angiogenesis caused by NK cell-secreted IFN-gamma PMID: 24313893
  93. indicate that knockdown of any component of the novel mut-p53/c-Myc/Bcl-XL axis and complex reversed the oncogenic effects of PTEN. PMID: 23908595
  94. identified inositol trisphosphate receptors as unique effectors of K-Ras4B that antagonize the prosurvival signals of other K-Ras effectors. PMID: 24297914
  95. these data suggest the efficacy of agents that target the MAPK and PI3K pathways can be improved by combination with a Bcl-2 family inhibitor. PMID: 23475955
  96. Simultaneously blocking EGFR, IGF1R and Bcl-xl genes is capable of altering the balance between proliferating versus apoptotic and senescent cells in the favor of both of apoptosis and senescence and, therefore, the tumor cells regression. PMID: 24055032
  97. the anti-tumor effect of miR-133a was probably due to targeting and repressing of Bcl-xL and Mcl-1 expression. PMID: 23756231
  98. our results suggest that upregulation of Bcl-xL in MPNST-derived SCs may be caused by the NF1 deficiency-mediated elevation in Ras/MAPK signaling and may provide a new potential chemotherapeutic target in patients with NF1 and MPNSTs. PMID: 23292448
  99. the level of human Bcl-xL is constantly modulated by deamidation. PMID: 23823868
  100. The hydrophobic core in Bcl-x(L) composed of Trp137, Ile140, Trp181, Ile182, Trp188 and Phe191 is highly conserved and essential for protein folding, protein stability and binding affinity with BH3-peptide. PMID: 22486615

Show More

Hide All

Subcellular Location Isoform Bcl-X(L): Mitochondrion inner membrane, Mitochondrion outer membrane, Mitochondrion matrix, Cytoplasmic vesicle, secretory vesicle, synaptic vesicle membrane, Cytoplasm, cytosol, Cytoplasm, cytoskeleton, microtubule organizing center, centrosome, Nucleus membrane, Single-pass membrane protein, Cytoplasmic side
Protein Families Bcl-2 family
Tissue Specificity Bcl-X(S) is expressed at high levels in cells that undergo a high rate of turnover, such as developing lymphocytes. In contrast, Bcl-X(L) is found in tissues containing long-lived postmitotic cells, such as adult brain.
Database Links

HGNC: 992

OMIM: 600039

KEGG: hsa:598

STRING: 9606.ENSP00000302564

UniGene: Hs.516966

Most popular with customers


Get all the latest information on Events, Sales and Offers. Sign up for newsletter today.

© 2007-2020 CUSABIO TECHNOLOGY LLC All rights reserved. 鄂ICP备15011166号-1